While targeting ATCase is a promising therapeutic strategy, there are several challenges to consider. One major challenge is achieving specificity, as inhibiting ATCase in normal cells could lead to toxicity and adverse effects. Additionally, cancer cells may develop resistance mechanisms, such as upregulating alternative pathways for pyrimidine synthesis. Overcoming these challenges requires a deep understanding of the enzyme's role in cancer biology and the development of highly specific inhibitors.
